IDEXX LABORATORIES INC /DE Deferred Tax Assets, in Process Research and Development
IDEXX LABORATORIES INC /DE (IDXX) had Deferred Tax Assets, in Process Research and Development of $2.02 million as of 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment · last filed 2026-02-20
- 2025-12-31: Deferred Tax Assets, in Process Research and Development $2.02M.
- 2024-12-31: Deferred Tax Assets, in Process Research and Development $92.86M.
- 2023-12-31: Deferred Tax Assets, in Process Research and Development $66.70M.
- 2022-12-31: Deferred Tax Assets, in Process Research and Development $30.00M.
| Period end | Deferred Tax Assets, in Process Research and Development |
|---|---|
| 2025-12-31 | $2.02M 10-K · filed 2026-02-20 |
| 2024-12-31 | $92.86M 10-K · filed 2026-02-20 |
| 2023-12-31 | $66.70M 10-K · filed 2025-02-21 |
| 2022-12-31 | $30.00M 10-K · filed 2024-02-22 |
| 2021-12-31 | $0.00 10-K · filed 2023-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |